BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/24/2022 9:00:24 AM | Browse: 496 | Download: 1265
 |
Received |
|
2021-10-31 03:52 |
|
Peer-Review Started |
|
2021-10-31 03:53 |
|
First Decision by Editorial Office Director |
|
2022-03-07 02:03 |
|
Return for Revision |
|
2022-03-07 02:03 |
|
Revised |
|
2022-04-10 06:51 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-05-11 03:02 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-05-12 19:44 |
|
Articles in Press |
|
2022-05-12 19:44 |
|
Edit the Manuscript by Language Editor |
|
2022-05-03 00:12 |
|
Typeset the Manuscript |
|
2022-06-16 01:01 |
|
Publish the Manuscript Online |
|
2022-06-24 09:00 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Hematology |
| Manuscript Type |
Case Report |
| Article Title |
Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yuan-Yuan Hao, Pan-Pan Chen, Xiang-Gui Yuan, Ai-Qi Zhao, Yun Liang, Hui Liu and Wen-Bin Qian |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wen-Bin Qian, MD, PhD, Doctor, Doctor, Professor, Department of Hematology, The Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China. qianwb@zju.edu.cn |
| Key Words |
Chimeric antigen receptor T cell therapy; Diffuse large B-cell lymphoma; Immunotherapy; PD-1 inhibitor; Histone deacetylase inhibitor; Case report |
| Core Tip |
We used histone deacetylase inhibitor chidamide combined with PD-1 blockade sintilimab for 7 patients with diffuse large B-cell lymphoma progressing after CART therapy. There are 2 complete response rates (CRs) and 2 PRs during this novel therapy, with an overall response rates of 57.1%, and one patient had a durable CR that lasted at least 20 mo. |
| Publish Date |
2022-06-24 09:00 |
| Citation |
Hao YY, Chen PP, Yuan XG, Zhao A, Liang Y, Liu H, Qian W. Histone deacetylase inhibitor chidamide and PD-1 blockade combination in diffuse large B-cell lymphoma progressing after CD19-targeting chimeric antigen receptor T cells therapy. World J Clin Cases 2022; 10(19): 6555-6562 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i19/6555.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i19.6555 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
